Clinical Trials

{
  "url": "https://clinicaltrials.gov/study/NCT05514106",
  "title": "MIBG in Aging and Neurologic Disorders",
  "nct_id": "NCT05514106",
  "phases": [
    "PHASE4"
  ],
  "source": "clinicaltrials.gov",
  "status": "ENROLLING_BY_INVITATION",
  "conditions": [
    "Lewy Body Disease",
    "Dementia",
    "Parkinsonism",
    "Mild Cognitive Impairment",
    "REM Sleep Behavior Disorder"
  ],
  "enrollment": 50,
  "study_type": "INTERVENTIONAL",
  "lead_sponsor": "Mayo Clinic",
  "published_at": "2026-07-30T00:00:00.000Z",
  "interventions": [
    {
      "name": "meta-iodobenzylguanidine (MIBG) (123I)",
      "type": "DRUG"
    },
    {
      "name": "123I-MIBG scintigraphy",
      "type": "DIAGNOSTIC_TEST"
    }
  ],
  "sponsor_class": "OTHER",
  "official_title": "Myocardial 123I-MIBG Scintigraphy in Aging and Neurodegenerative Disease",
  "first_posted_at": "2022-08-24T00:00:00.000Z"
}

{
  "url": "https://clinicaltrials.gov/study/NCT06570798",
  "title": "A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases",
  "nct_id": "NCT06570798",
  "phases": [
    "PHASE2"
  ],
  "source": "clinicaltrials.gov",
  "status": "RECRUITING",
  "conditions": [
    "Systemic Lupus Erythematosus",
    "Active Refractory Rheumatoid Arthritis"
  ],
  "enrollment": 220,
  "study_type": "INTERVENTIONAL",
  "lead_sponsor": "Amgen",
  "published_at": "2026-07-30T00:00:00.000Z",
  "interventions": [
    {
      "name": "Inebilizumab",
      "type": "DRUG"
    },
    {
      "name": "Blinatumomab",
      "type": "DRUG"
    }
  ],
  "sponsor_class": "INDUSTRY",
  "official_title": "A Phase 2, Open Label, Multicenter, Platform Trial to Assess the Safety, Tolerability, and Efficacy of Inebilizumab and Blinatumomab in Subjects With Autoimmune Diseases",
  "first_posted_at": "2024-08-26T00:00:00.000Z"
}

{
  "url": "https://clinicaltrials.gov/study/NCT07738016",
  "title": "Artificially Intelligent Robotic Control",
  "nct_id": "NCT07738016",
  "phases": [
    "NA"
  ],
  "source": "clinicaltrials.gov",
  "status": "NOT_YET_RECRUITING",
  "conditions": [
    "Asthma in Children",
    "Artificial Intelligence",
    "Caregiver Burden"
  ],
  "enrollment": 80,
  "study_type": "INTERVENTIONAL",
  "lead_sponsor": "University of Miami",
  "published_at": "2026-07-30T00:00:00.000Z",
  "interventions": [
    {
      "name": "Artificially Intelligent Robot (AIR) Control Intervention",
      "type": "BEHAVIORAL"
    },
    {
      "name": "Standard Asthma Education",
      "type": "BEHAVIORAL"
    }
  ],
  "sponsor_class": "OTHER",
  "official_title": "Asthma Under Artificially Intelligent Robotic (AIR) Control: Robotic Support for Pediatric Education",
  "first_posted_at": "2026-07-30T00:00:00.000Z"
}

{
  "url": "https://clinicaltrials.gov/study/NCT06068257",
  "title": "Tumor-Derived FGF19",
  "nct_id": "NCT06068257",
  "phases": [],
  "source": "clinicaltrials.gov",
  "status": "COMPLETED",
  "conditions": [
    "Colorectal Cancer",
    "Breast Cancer",
    "Healthy"
  ],
  "enrollment": 119,
  "study_type": "OBSERVATIONAL",
  "lead_sponsor": "University of Central Florida",
  "published_at": "2026-07-30T00:00:00.000Z",
  "interventions": [],
  "sponsor_class": "OTHER",
  "official_title": "Translational Utility of Tumor-Derived FGF19 in a Novel Blood-Based Endocrine Suppression Approach",
  "first_posted_at": "2023-10-05T00:00:00.000Z"
}

{
  "url": "https://clinicaltrials.gov/study/NCT07726732",
  "title": "B4B Evolution Type II Hybrid Effectiveness-Implementation Trial",
  "nct_id": "NCT07726732",
  "phases": [
    "NA"
  ],
  "source": "clinicaltrials.gov",
  "status": "ENROLLING_BY_INVITATION",
  "conditions": [
    "Physical Activity",
    "Sedentary Behavior",
    "Cognition",
    "Academic Acheivement"
  ],
  "enrollment": 300,
  "study_type": "INTERVENTIONAL",
  "lead_sponsor": "University of the Balearic Islands",
  "published_at": "2026-07-30T00:00:00.000Z",
  "interventions": [
    {
      "name": "Break4Brain Evolution",
      "type": "BEHAVIORAL"
    }
  ],
  "sponsor_class": "OTHER",
  "official_title": "Classroom Movement Strategies to Increase Physical Activity and Improve Cognition and Academic Performance in a School-Aged Population: Protocol for the Break4Brain Type II Hybrid Effectiveness-Implementation Trial",
  "first_posted_at": "2026-07-24T00:00:00.000Z"
}

{
  "url": "https://clinicaltrials.gov/study/NCT06586437",
  "title": "Neuromodulation of the Cortex and Spinal Cord",
  "nct_id": "NCT06586437",
  "phases": [
    "NA"
  ],
  "source": "clinicaltrials.gov",
  "status": "ACTIVE_NOT_RECRUITING",
  "conditions": [
    "Cerebral Palsy"
  ],
  "enrollment": 50,
  "study_type": "INTERVENTIONAL",
  "lead_sponsor": "Father Flanagan's Boys' Home",
  "published_at": "2026-07-30T00:00:00.000Z",
  "interventions": [
    {
      "name": "Clinical Assessments",
      "type": "BEHAVIORAL"
    },
    {
      "name": "Brain-Spinal Cord fMRI",
      "type": "BEHAVIORAL"
    },
    {
      "name": "Hoffmann Reflex Assessments",
      "type": "BEHAVIORAL"
    },
    {
      "name": "MEG Imaging",
      "type": "BEHAVIORAL"
    },
    {
      "name": "Transcutaneous Current Stimulation",
      "type": "BEHAVIORAL"
    }
  ],
  "sponsor_class": "OTHER",
  "official_title": "Neuromodulation of the Cortex and Spinal Cord",
  "first_posted_at": "2024-09-19T00:00:00.000Z"
}

{
  "url": "https://clinicaltrials.gov/study/NCT07736911",
  "title": "Discontinuation One Week Recommendations for GLP-1 Receptor Agonists Prior to Esophagogastroduodenoscopy.",
  "nct_id": "NCT07736911",
  "phases": [
    "PHASE3"
  ],
  "source": "clinicaltrials.gov",
  "status": "RECRUITING",
  "conditions": [
    "GLP-1"
  ],
  "enrollment": 140,
  "study_type": "INTERVENTIONAL",
  "lead_sponsor": "Fu Jen Catholic University Hospital",
  "published_at": "2026-07-30T00:00:00.000Z",
  "interventions": [
    {
      "name": "Stop for 1 week",
      "type": "DRUG"
    },
    {
      "name": "GLP-1 non stop",
      "type": "DRUG"
    }
  ],
  "sponsor_class": "OTHER",
  "official_title": "Discontinuation One Week Recommendations for GLP-1 Receptor Agonists Prior to Esophagogastroduodenoscopy: A Randomized Controlled Trial.",
  "first_posted_at": "2026-07-30T00:00:00.000Z"
}

{
  "url": "https://clinicaltrials.gov/study/NCT07735611",
  "title": "Robotic Systems Evaluation for Peripheral Pulmonary Lesions (RISE Trial)",
  "nct_id": "NCT07735611",
  "phases": [
    "NA"
  ],
  "source": "clinicaltrials.gov",
  "status": "NOT_YET_RECRUITING",
  "conditions": [
    "Lung; Node"
  ],
  "enrollment": 398,
  "study_type": "INTERVENTIONAL",
  "lead_sponsor": "Case Comprehensive Cancer Center",
  "published_at": "2026-07-30T00:00:00.000Z",
  "interventions": [
    {
      "name": "RAB via the Monarch platform",
      "type": "PROCEDURE"
    },
    {
      "name": "RAB via the ION platform",
      "type": "PROCEDURE"
    }
  ],
  "sponsor_class": "OTHER",
  "official_title": "Robotic Systems Evaluation for Peripheral Pulmonary Lesions: A Randomized Trial (RISE Trial)",
  "first_posted_at": "2026-07-30T00:00:00.000Z"
}

{
  "url": "https://clinicaltrials.gov/study/NCT02506153",
  "title": "Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery",
  "nct_id": "NCT02506153",
  "phases": [
    "PHASE3"
  ],
  "source": "clinicaltrials.gov",
  "status": "ACTIVE_NOT_RECRUITING",
  "conditions": [
    "Clinical Stage III Cutaneous Melanoma AJCC v8",
    "Clinical Stage IV Cutaneous Melanoma AJCC v8",
    "Metastatic Cutaneous Melanoma",
    "Metastatic Mucosal Melanoma",
    "Metastatic Non-Cutaneous Melanoma",
    "Non-Cutaneous Melanoma",
    "Recurrent Cutaneous Melanoma",
    "Recurrent Mucosal Melanoma",
    "Recurrent Non-Cutaneous Melanoma"
  ],
  "enrollment": 1301,
  "study_type": "INTERVENTIONAL",
  "lead_sponsor": "National Cancer Institute (NCI)",
  "published_at": "2026-07-30T00:00:00.000Z",
  "interventions": [
    {
      "name": "Biospecimen Collection",
      "type": "PROCEDURE"
    },
    {
      "name": "Computed Tomography",
      "type": "PROCEDURE"
    },
    {
      "name": "Ipilimumab",
      "type": "BIOLOGICAL"
    },
    {
      "name": "Magnetic Resonance Imaging",
      "type": "PROCEDURE"
    },
    {
      "name": "Pembrolizumab",
      "type": "BIOLOGICAL"
    },
    {
      "name": "Positron Emission Tomography",
      "type": "PROCEDURE"
    },
    {
      "name": "Quality-of-Life Assessment",
      "type": "OTHER"
    },
    {
      "name": "Recombinant Interferon Alfa-2b",
      "type": "BIOLOGICAL"
    }
  ],
  "sponsor_class": "NIH",
  "official_title": "A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma",
  "first_posted_at": "2015-07-23T00:00:00.000Z"
}

{
  "url": "https://clinicaltrials.gov/study/NCT04543097",
  "title": "Work And Vocational advicE Study - Effectiveness of Adding a Brief Vocational Support Intervention to Usual Primary Care",
  "nct_id": "NCT04543097",
  "phases": [
    "NA"
  ],
  "source": "clinicaltrials.gov",
  "status": "TERMINATED",
  "conditions": [
    "Musculoskeletal Pain",
    "Mental Health Issue",
    "Mental Health Disorder",
    "Other Physical Health Condition",
    "Absence"
  ],
  "enrollment": 130,
  "study_type": "INTERVENTIONAL",
  "lead_sponsor": "Keele University",
  "published_at": "2026-07-30T00:00:00.000Z",
  "interventions": [
    {
      "name": "Vocational Support",
      "type": "BEHAVIORAL"
    }
  ],
  "sponsor_class": "OTHER",
  "official_title": "Work And Vocational advicE (WAVE) in Primary Care: a Randomised Controlled Trial",
  "first_posted_at": "2020-09-09T00:00:00.000Z"
}